Walmart and Bank of America are expanding coverage, while 10% of surveyed employers say they may drop it in 2027. Workers explain what coverage means for their budgets.
Recap by typeshit. Full story at CNBC.
GEN ranks the best-selling drugs by 2025 sales, and Lilly's weight loss shot outpaced names like Merck's Keytruda on growth.
A Dongguk University family medicine professor calls gallbladder risk the real concern and says some Koreans fly to Japan, where the drugs reportedly cost about a third.
Ricks describes working with the Trump administration to lower obesity drug costs for older Americans, on the day Lilly posted third-quarter earnings.
The first four weeks cost around 129,800 won at supply price. Hanmi reports 9.75% average weight loss over 40 weeks and has set a 100 billion won first-year sales target.
Varon says some of his patients still have diarrhea after meals years after stopping, though the interview didn't show the drugs caused it. He also points to thyroid findings in animals.
Lilly now expects $91 to $92 billion in revenue this year. Its oral GLP-1 Foundayo brought in $184 million, short of what analysts expected.
Loading…